KRAS G12C Mutation: An Emerging Biomarker for NSCLC Sponsored by Amgen®
IE users – if you are experiencing issues trying to register for this webinar, please use Chrome, Safari or Firefox.
Tuesday, December 15, 2020
12:00PM ET/ 9:00 AM PT
Program objectives
At the conclusion of this program, participants will be able to:
• Discuss the evolution of biomarkers in NSCLC
• Describe KRAS and KRAS G12C prevalence information
• Explain diagnostic strategies and options for KRAS G12C testing
Speakers:
Yuri Fesko, MD
Chief Clinical Officer, Oncology Quest Diagnostics
Secaucus, New Jersey
Kari Hooper, MD
Pathologist, AmeriPath®/Quest Diagnostics Department Chair,
Integris Baptist Medical Center Oklahoma City, Oklahoma
